Answers are grounded in this paper and cite their sources.
Animal study demonstrates improved motor function and stem cell survival in a rat stroke model, indicating a viable regenerative biomaterial platform for tissue repair.
Stroke is a leading cause of disability worldwide, yet effective treatments to regenerate damaged tissue remain elusive. We investigated tissue regeneration and functional recovery post-stroke in an animal model with a combinatorial approach leveraging human induced pluripotent stem cell-derived neural progenitor cells (NPCs) and a sustained-release formulation of a re-designed, thermostable chondroitinase ABC (ChASE37). We optimized an in situ gelling, injectable hyaluronic acid (HA)-based hydrogel with the incorporation of laminin to deliver NPCs to the cavity in a rat model of sub-acute ischemic stroke. We delivered ChASE37 by affinity release from a methylcellulose hydrogel (ChASE37-AR) to the stroke-injured brain by epicortical injection. ChASE37-AR retained long-term enzymatic activity, as demonstrated by degradation of inhibitory chondroitin sulfate proteoglycans (CSPGs) in the injured tissue, with no evidence of immunogenicity. Each treatment - ChASE37-AR, NPCs, and their co-delivery - significantly improved motor function as early as 3 weeks after a single administration. Critically, only the combined therapy supported long-term survival and neuronal differentiation of transplanted cells, suggesting that ChASE37-AR has a role beyond CSPG degradation. This strategy presents a modular, clinically relevant platform for tissue regeneration post-stroke. Together, these findings suggest that the co-delivery of NPCs and sustained-release ChASE37 may be promising for stroke treatment.
No takes yet. Share an insight, caveat, or question.
Khait et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: